Register entry

Ocuvex Therapeutics, Inc.

Data as of · How to read this entry

Registered sites
0
Active NDC listings
1
Live patents
13
Exclusivities
1
Countries
0
Exclusivity

Patents and exclusivities

13
PatentProductCoversExpiry
8648097OMLONTIomidenepag isopropylsubstance, productOct 2029
8685986OMLONTIomidenepag isopropylproductOct 2029
10179127OMLONTIomidenepag isopropylproductJan 2035
10702511OMLONTIomidenepag isopropylproductJan 2035
10765750OMLONTIomidenepag isopropylproductJan 2035
11197849OMLONTIomidenepag isopropylproductJan 2035
11793798OMLONTIomidenepag isopropylproductJan 2035
12295946OMLONTIomidenepag isopropylproductJan 2035
9415038OMLONTIomidenepag isopropylproductJan 2035
RE48183OMLONTIomidenepag isopropylproductJan 2035
10774072OMLONTIomidenepag isopropylsubstanceJun 2035
12290511OMLONTIomidenepag isopropyluseDec 2038
11666563OMLONTIomidenepag isopropyluseJul 2039
ProductExclusivityUntil
OMLONTIOMIDENEPAG ISOPROPYLNCE New chemical entitySept 2027
Catalogue

Marketed products

1
BrandGeneric nameForm / routeNDC
Omlontiomidenepag isopropylsolution/ drops, ophthalmic84826-002NDA
Enquiry

Common questions

Is Ocuvex Therapeutics, Inc. FDA approved?
Ocuvex Therapeutics, Inc. holds no registered establishment of its own; 1 drug product is listed under its name in the National Drug Code Directory, made at sites registered to other firms.
What drugs does Ocuvex Therapeutics, Inc. make?
1 product is listed under Ocuvex Therapeutics, Inc. in the openFDA NDC Directory, most often as solution/ drops. The full breakdown by dosage form and route is above. A listing count is not a sales figure.

Compiled from FDA establishment registrations, the openFDA NDC Directory, the Orange Book and the FDA drug shortage database. Not claimed by the company. Sources and methodology.